Navigation Links
Sagent Pharmaceuticals Launches Ceftazidime for Injection, USP
Date:7/24/2008

SCHAUMBURG, Ill., July 24 /PRNewswire/ -- Sagent Pharmaceuticals, Inc., a privately-held specialty pharmaceutical company, today announced that it has launched ceftazidime for injection, USP, a semisynthetic broad-spectrum, beta-lactam antibiotic. Sagent will offer ceftazidime in 1 and 2g single dose vials and 6g pharmacy bulk package vials. According to IMS data, 2007 sales of injectable amiodarone in the United States were approximately $45.7 million.

"Sagent is proud to be providing tools to the healthcare community that have the potential to help reduce medical errors," said Jeffrey M. Yordon, chief executive officer, founder, and chairman of the board of Sagent. "We are excited to make important products like ceftazidime available with exciting innovations, such as easy-to-read dosage strengths and precise lettering on vial labels that are intended to promote patient safety."

Sagent's introduction of ceftazidime to the U.S. market is the seventh product launched from Sagent's pipeline of more than 200 products this year.

About Ceftazidime

Ceftazidime for Injection, USP is a semisynthetic broad-spectrum, beta-lactam antibiotic used to treat bacterial infections, including infections of the lower respiratory tract; skin and skin-structure; urinary tract; bone and joint; and central nervous system. Ceftazidime is also indicated for bacterial septicemia, gynecologic infections, and intra-abdominal infections. Sagent's ceftazidime is the generic equivalent of GlaxoSmithKline's FORTAZ(R).

The most common adverse effects include diarrhea, headache, stomach pain, nausea, vomiting, and numbness or tingling of the skin. Less common adverse effects include abnormal muscle movements, severe stomach cramps, severe nausea or vomiting, bloody stools, severe diarrhea, decreased urination, vaginal irritation or discharge, fever, white patches in the mouth, hoarseness, jaundice, injection site reactions, vein inflammation and red, swollen or blistered skin, seizures.

About Sagent Pharmaceuticals, Inc.

Sagent Pharmaceuticals, founded in 2006, is a privately held specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectable products. Sagent has created a unique, global network of resources, comprised of rapid development capabilities, sophisticated manufacturing and innovative drug-delivery technologies, quickly yielding an extensive portfolio of pharmaceutical products that fulfills the evolving needs of patients. Sagent currently has more than 200 products in development.

To Discover Injectables Excellence(TM) and learn more about Sagent, please visit http://www.SagentPharma.com.


'/>"/>
SOURCE Sagent Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Sagent Pharmaceuticals Launches Ceftriaxone, USP, and Cefuroxime for Injection, USP
2. Sagent Pharmaceuticals Provides US$20,000 in Aid to Earthquake-Devastated Areas in Central China
3. Sagent Pharmaceuticals Launches Cefazolin for Injection, USP
4. Sagent Pharmaceuticals, Inc. to Present at Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
5. Anesiva Signs Co-Promotion and Distribution Agreement With Sagent Pharmaceuticals for Zingo(TM) in U.S. Hospitals
6. Peregrine Pharmaceuticals Receives Letter from NASDAQ Citing Failure to Regain Compliance with Minimum Bid Price Rule
7. Anadys Pharmaceuticals to Report Second Quarter 2008 Financial Results
8. Sonus Pharmaceuticals Receives Favorable NASDAQ Decision
9. Jazz Pharmaceuticals Announces $26.0 Million Registered Direct Offering
10. Amylin Pharmaceuticals to Webcast Second Quarter Results
11. ViroPharma To Acquire Lev Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... world leader in rapid infectious disease tests, introduced the Company,s newest product, the INSTI ... (Photo: http://photos.prnewswire.com/prnh/20161201/444905 ) Continue Reading ... ... , bioLytical was invited by the Clinton ... HIV Self Test to 350 pharmacy representatives in Nairobi and ...
(Date:11/30/2016)... today announced the appointment of Joshua F. Coleman , ... Dr. Coleman will oversee clinical content development and curation of ... software suite empowers molecular pathologists with a seamless workflow for ... from quality control through reporting. ... , , ...
(Date:11/30/2016)... Nov. 30, 2016 /PRNewswire/ - Portage Biotech Inc. ("Portage" ... PBT.U), is excited to announce the formation of ... developing preclinical ophthalmology assets through proof of concept. ... created by Portage Pharmaceuticals Limited and being developed ... surface and anterior segment diseases. This agent has ...
(Date:11/30/2016)... 2016  The Allen Institute for Cell Science ... publicly available collection of gene edited, fluorescently tagged ... cellular structures with unprecedented clarity. Distributed through the ... are a crucial first step toward visualizing the ... makes human cells healthy and what goes wrong ...
Breaking Biology Technology:
(Date:11/29/2016)... , Nov. 29, 2016   Neurotechnology ... and object recognition technologies, today released FingerCell ... fingerprint recognition solutions that run on low-power, ... template using less than 128KB of memory, ... devices that have limited on-board resources, such ...
(Date:11/22/2016)... According to the new market research report "Biometric ... Signature, Voice), Multi-Factor), Component (Hardware and Software), Function (Contact and Non-contact), Application, ... is expected to grow from USD 10.74 Billion in 2015 to reach ... and 2022. Continue Reading ... ...
(Date:11/17/2016)... 17, 2016 Global Market Watch: Primarily ... Banks, Population-Based Banks and Academics) market is to witness a ... Biobanks shows the highest Compounded Annual Growth Rate (CAGR) of ... during the analysis period 2014-2020. North America ... followed by Europe at 9.56% respectively. ...
Breaking Biology News(10 mins):